PET to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
Research type
Research Study
Full title
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in Hypertrophic Obstructive Cardiomyopathy: The PEACH-Trial
IRAS ID
349544
Contact name
Andrew Crean
Contact email
Sponsor organisation
The University of Manchester
Clinicaltrials.gov Identifier
N/a, N/a
Duration of Study in the UK
2 years, 6 months, 3 days
Research summary
Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition that leads to the thickening of the heart muscle and causes obstruction of blood flow, impeding its ejection from the heart (LVOT obstruction). Often individuals with HOCM suffer from chest pain and shortness of breath due to lack of oxygen supply (ischaemia) to the heart in the absence of blockages in the heart vessels.
Despite proven advances in treatment of LVOT obstruction with the novel medication Mavacamten, there is a limited understanding of its effect on myocardial ischaemia. We aim to address a critical knowledge gap: whether reducing LVOT obstruction with Mavacamten also leads to improvements in myocardial ischaemia, thereby alleviating symptoms like angina and improving quality of life. This study will fill the knowledge gap by assessing improvement in myocardial perfusion one year after Mavacamten treatment has been initiated.
This research does not repeat any previous studies. While prior trials, such as the EXPLORER-HCM study, have elegantly demonstrated Mavacamten's efficacy in reducing LVOT obstruction and improving patients' exercise capacity, no dedicated research studies have focused on its impact on myocardial ischaemia, which is the unique focus of this study.
As a PhD student research project, it will provide valuable education in clinical research methodology, critical thinking and problem-solving. Research student will be exposed to ethical considerations, patient recruitment, and the application of statistical methods to analyse complex clinical and imaging (Rubidium PET-CT) data.
As part of a larger scientific effort to improve patient outcomes, it will offer hands-on experience in the practical aspects of conducting and analysing a prospective observational cohort study. Moreover, if proven effective, Mavacamten could enhance currently available treatment strategies, addressing both the mechanical outflow obstruction and ischaemic components of the disease.REC name
East of Scotland Research Ethics Service REC 1
REC reference
25/ES/0044
Date of REC Opinion
18 Jul 2025
REC opinion
Further Information Favourable Opinion